Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stijn L W Koolen

Showing results (41-50 of 125) with videos related to

Pageof 13
Sort By:
Pharmaceuticals (Basel, Switzerland)|January 13, 2021
The Influence of Body Composition on the Systemic Exposure of Paclitaxel in Esophageal Cancer PatientsLeni van Doorn, Marie-Rose B S Crombag, Hánah N Rier, et al.
Cancers|July 2, 2021
Population Pharmacokinetics of Oxycodone and Metabolites in Patients with Cancer-Related PainBram C Agema, Astrid W Oosten, Sebastiaan D T Sassen, et al.
Pharmaceutical Research|October 17, 2019
Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?Marie-Rose B S Crombag, Stijn L W Koolen, Sophie Wijngaard, et al.
Journal of Pharmaceutical and Biomedical Analysis|May 17, 2021
Quantification of ribociclib in dried blood spots by LC-MS/MS: Method development and clinical validationC Louwrens Braal, Mei H Lam, Tineke Rienks, et al.
Current Clinical Pharmacology|November 14, 2013
Phase II and pharmacological study of oral docetaxel plus cyclosporin A in anthracycline pre-treated metastatic breast cancerHelgi H Helgason, Stijn L W Koolen, Erik van Werkhoven, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 8, 2023
Toward model-informed precision dosing for tamoxifen: A population-pharmacokinetic model with a continuous CYP2D6 activity scaleBram C Agema, Sanne M Buijs, Sebastiaan D T Sassen, et al.
Plos One|June 9, 2018
Effects of smoking and body mass index on the exposure of fentanyl in patients with cancerEvelien J M Kuip, Wendy H Oldenmenger, Martine F Thijs-Visser, et al.
Clinical Pharmacokinetics|February 6, 2020
Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer PatientsStefanie L Groenland, Ruben A G van Eerden, Remy B Verheijen, et al.
Clinical Pharmacokinetics|September 27, 2024
Selecting the Best Pharmacokinetic Models for a Priori Model-Informed Precision Dosing with Model EnsemblingBram C Agema, Tolra Kocher, Ayşenur B Öztürk, et al.
EJNMMI Radiopharmacy and Chemistry|November 5, 2022
Radiolabeling and quality control of therapeutic radiopharmaceuticals: optimization, clinical implementation and comparison of radio-TLC/HPLC analysis, demonstrated by [<sup>177</sup>Lu]Lu-PSMAEline L Hooijman, Carolline M Ntihabose, Thom G A Reuvers, et al.
Pageof 13

Showing results (41-50 of 125) with videos related to

Sort By:
Pageof 13
Pharmaceuticals (Basel, Switzerland)|January 13, 2021
The Influence of Body Composition on the Systemic Exposure of Paclitaxel in Esophageal Cancer PatientsLeni van Doorn, Marie-Rose B S Crombag, Hánah N Rier, et al.
Cancers|July 2, 2021
Population Pharmacokinetics of Oxycodone and Metabolites in Patients with Cancer-Related PainBram C Agema, Astrid W Oosten, Sebastiaan D T Sassen, et al.
Pharmaceutical Research|October 17, 2019
Does Older Age Lead to Higher Risk for Neutropenia in Patients Treated with Paclitaxel?Marie-Rose B S Crombag, Stijn L W Koolen, Sophie Wijngaard, et al.
Journal of Pharmaceutical and Biomedical Analysis|May 17, 2021
Quantification of ribociclib in dried blood spots by LC-MS/MS: Method development and clinical validationC Louwrens Braal, Mei H Lam, Tineke Rienks, et al.
Current Clinical Pharmacology|November 14, 2013
Phase II and pharmacological study of oral docetaxel plus cyclosporin A in anthracycline pre-treated metastatic breast cancerHelgi H Helgason, Stijn L W Koolen, Erik van Werkhoven, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 8, 2023
Toward model-informed precision dosing for tamoxifen: A population-pharmacokinetic model with a continuous CYP2D6 activity scaleBram C Agema, Sanne M Buijs, Sebastiaan D T Sassen, et al.
Plos One|June 9, 2018
Effects of smoking and body mass index on the exposure of fentanyl in patients with cancerEvelien J M Kuip, Wendy H Oldenmenger, Martine F Thijs-Visser, et al.
Clinical Pharmacokinetics|February 6, 2020
Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer PatientsStefanie L Groenland, Ruben A G van Eerden, Remy B Verheijen, et al.
Clinical Pharmacokinetics|September 27, 2024
Selecting the Best Pharmacokinetic Models for a Priori Model-Informed Precision Dosing with Model EnsemblingBram C Agema, Tolra Kocher, Ayşenur B Öztürk, et al.
EJNMMI Radiopharmacy and Chemistry|November 5, 2022
Radiolabeling and quality control of therapeutic radiopharmaceuticals: optimization, clinical implementation and comparison of radio-TLC/HPLC analysis, demonstrated by [<sup>177</sup>Lu]Lu-PSMAEline L Hooijman, Carolline M Ntihabose, Thom G A Reuvers, et al.
Pageof 13